EAPIN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
API Supplier ModelEuroapi operates in a specialized business-to-business role supporting drug production, with revenue from both commercial API manufacturing and lifecycle services. This combination can deepen customer relationships and create recurring demand as molecules progress from development into industrial-scale supply.
Conservative LeverageVery low leverage gives Euroapi greater financial flexibility than a highly indebted manufacturer and reduces pressure from interest obligations. This balance-sheet capacity can help the company manage operational volatility, fund necessary investment, and withstand periods of weaker pharmaceutical demand.
Improved Cash GenerationThe return to positive operating and free cash flow in 2024–2025 indicates that the business has recently converted operations into cash despite reported losses. Sustained cash generation would improve self-funding capacity and support investment without relying heavily on additional borrowing.
Bears Say
Declining RevenueRecent revenue contraction points to weaker commercial momentum and makes it harder for Euroapi to absorb fixed manufacturing and development costs. If declining sales persist, capacity utilization and operating leverage could remain under pressure, limiting the durability of any margin improvement.
Persistent Widening LossesDeeply negative and widening net income shows that improved EBITDA has not translated into sustainable bottom-line profitability. Continued non-operating costs or charges could consume cash and weaken retained equity, making long-term earnings recovery dependent on substantial execution improvement.
Volatile Cash ConversionAlthough recent free cash flow is positive, its history of losses and sharp changes indicates that cash conversion is not yet consistently dependable. Working-capital or execution swings could reduce funds available for investment and make the company more reliant on balance-sheet resources during weaker periods.
Euroapi SA News
EAPIN FAQ
What was Euroapi SA’s price range in the past 12 months?
Currently, no data Available
What is Euroapi SA’s market cap?
Euroapi SA’s market cap is $1.56B.
When is Euroapi SA’s upcoming earnings report date?
Euroapi SA’s upcoming earnings report date is Mar 09, 2027 which is in 177 days.
How were Euroapi SA’s earnings last quarter?
Euroapi SA released its earnings results on Jul 29, 2026. The company reported -$29.426 earnings per share for the quarter.
Is Euroapi SA overvalued?
According to Wall Street analysts Euroapi SA’s price is currently Undervalued.
Does Euroapi SA pay dividends?
Euroapi SA does not currently pay dividends.
What is Euroapi SA’s EPS estimate?
Euroapi SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Euroapi SA have?
Euroapi SA has 96,010,155 shares outstanding.
What happened to Euroapi SA’s price movement after its last earnings report?
Euroapi SA reported an EPS of -$29.426 in its last earnings report. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Euroapi SA?
Currently, no hedge funds are holding shares in MX:EAPIN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Euroapi SA
Headquartered in Paris, France, Euroapi SA, founded in 2021, specializes in the research, production, promotion, and delivery of active pharmaceutical ingredients (APIs) and chemical intermediates. These vital components are utilized in the development of both human and animal medical treatments.